Guidance
← 실적 발표
01
02
03
04 05 06
톤
AI
자본지출
A1 A2
TMO
FY2025 Q3
상향
Thermo Fisher Scientific Inc 실적 발표
Buzzberg 분석
Guidance raised for full-year 2025 revenue and EPS.
Thermo Fisher delivered a strong Q3 with 5% revenue growth and raised full-year guidance. Management highlighted strategic collaborations with OpenAI and AstraZeneca, completed acquisitions of Solventum's filtration business and a Sanofi fill-finish site, and noted increasing pharma reshoring activity. Academic/government end market remained weak but showed modest improvement. Q3 revenue $11.12B (+5% y/y), adjusted EPS $5.79 (+10%), operating margin 23.3% (+100 bps).
Buzzberg 분석 Guidance raised for full-year 2025 revenue and EPS. Thermo Fisher delivered a strong Q3 with 5% revenue growth and raised full-year guidance. Management highlighted strategic collaborations with OpenAI and AstraZeneca, completed acquisitions of Solventum's filtration business and a Sanofi fill-finish site, and noted increasing pharma reshoring activity. Academic/government end market remained weak but showed modest improvement. Q3 revenue $11.12B (+5% y/y), adjusted EPS $5.79 (+10%), operating margin 23.3% (+100 bps). 전체 분석 보기분석 접기
Thermo Fisher delivered a strong Q3 with 5% revenue growth and raised full-year guidance. Management highlighted strategic collaborations with OpenAI and AstraZeneca, completed acquisitions of Solventum's filtration business and a Sanofi fill-finish site, and noted increasing pharma reshoring activity. Academic/government end market remained weak but showed modest improvement. Q3 revenue $11.12B (+5% y/y), adjusted EPS $5.79 (+10%), operating margin 23.3% (+100 bps).
- Full-year revenue guidance raised to $44.1-44.5B, EPS to $22.60-22.86.
- Collaboration with OpenAI to embed AI into clinical research and internal operations.
- Acquired Solventum filtration business (~$750M annual revenue) and Sanofi sterile fill-finish site.
매출$11.122B보고값
주당순이익(EPS)$5.79보고값
매출총이익률41.83%보고값
영업이익률17.47%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
AI
OpenAI partnership to embed AI in products and internal ops.
Demand
Clinical research business returns to low single-digit growth.
핵심 내용 3개 더 보기
Demand
Pharma reshoring conversations with customers are active.
Macro
Biotech funding and deal activity improving, aiding ecosystem.
Margins
Q3 EPS beat driven by strong operational performance, partly offset by acquisitions.
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $11.122B | 보고값 |
| 주당순이익(EPS) | $5.79 | 보고값 |
| 매출총이익률 | 41.83% | 보고값 |
| 영업이익률 | 17.47% | 보고값 |
| 잉여현금흐름 | $1.835B | 보고값 |
| 자본지출 | $0.404B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 자본지출 | FY2025 | $1.4B–$1.7B | $1.55B | 유지 |
| 주당순이익(EPS) | FY2025 | $22.60–$22.86 | $22.73 | 상향 |
| 잉여현금흐름 | FY2025 | $7B | $7B | 유지 |
| 영업이익률 | FY2025 | 22.7%–22.8% | 22.75% | 상향 |
| 매출 | FY2025 | $44.1B–$44.5B | $44.3B | 상향 |
AI, 자본지출 및 수요 분석
경영진 분석
Upbeat
Management expressed confidence in execution, raised guidance for the full year, and highlighted strong demand from pharma and biotech customers.
경영진의 AI 분석
Management discussed embedding OpenAI technology into products and services to improve clinical trial cycle times, and deploying ChatGPT Enterprise internally to drive productivity. They also mentioned co-creating capabilities leveraging data repository to add value for customers.
투자 및 생산능력
Management raised full-year 2025 capex guidance to $1.4-$1.7 billion net capital expenditures. They also highlighted investments in a new sterile fill-finish site in the U.S. and a manufacturing center of excellence in Mebane, North Carolina, to support reshoring and U.S. supply chain resilience.
아래에 언급된 기업 8개 모두 표시
기업발표 이후 수익률
파트너
OPENAI
파트너
Mark Masper
Thermo Fisher is tightly integrating OpenAI's AI into its products and internal operations, which could accelerate drug development and enhance competitive positioning.
근거
“We are embedding OpenAI advanced technology into critical areas of our business, including product development, service delivery, customer engagement, and operations.”
파트너
Mark Masper
Co-location of Thermo Fisher scientists with AstraZeneca could deepen R&D collaboration and drive instrument and consumables sales.
근거
“The recently announced strategic partnership with AstraZeneca BioVenture Hub in Gothenburg, Sweden.”
공급망
공급망
Mark Masper
Thermo Fisher adds bioprocessing and industrial filtration capabilities, expanding its addressable market and customer base.
근거
“We completed our acquisition of our filtration and separation business from Solventum, which is now part of our life sciences solution segment.”
공급망
Mark Masper
Thermo Fisher gains a new U.S. sterile fill-finish node with built-in Sanofi volume, supporting reshoring demand.
근거
“We closed our acquisition of the Ridgefield, New Jersey, sterile fill finish site from Sanofi, expanding our U.S. drug product manufacturing.”
공급망
Mark Masper
Thermo Fisher's new Mebane, NC facility can produce 40 million pipette tips per week, directly addressing U.S. lab consumable supply chain resilience. — Increases domestic capacity and may reduce reliance on Asian suppliers, pressuring competitors in the lab consumables space.
근거
“A high-volume, low-cost facility, this site was developed with support from the U.S. government and is capable of producing at least 40 million laboratory pipette tips per week.”
공급망
Mark Masper
Pharma customers are actively reshoring manufacturing to the U.S., creating near-term construction/equipment demand and long-term recurring consumables growth for Thermo Fisher. — Steers large pharma spending toward Thermo Fisher's U.S. sites and could shift market share from European CDMOs.
근거
“We are actively engaged in helping those customers think about new sites, how to best equip them, and support our customers in that effort.”
외부 신호
공급망 알파 · 2발표 이후 수익률
Thermo Fisher's new Mebane, NC facility can produce 40 million pipette tips per week, directly addressing U.S. lab consumable supply chain resilience.
Pharma customers are actively reshoring manufacturing to the U.S., creating near-term construction/equipment demand and long-term recurring consumables growth for Thermo Fisher.
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 8개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.